|
| Status |
Public on May 31, 2018 |
| Title |
Comparative gene expression profiling of MHH-CALL4 cells subject to pharmacological JAK2 inhibitor treatment (ruxolitinib or CHZ868) or shRNA-mediated JAK2 depletion in vitro |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Gene expression profiling was performed to characterise transcriptional programs associated with response to type I JAK2 inhibitor ruxolitinib, type II JAK2 inhibitor CHZ868 or shRNA-mediated JAK2 knockdown in MHH-CALL4 cells.
|
| |
|
| Overall design |
CRLF2-rearranged/JAK2I682F-expressing MHH-CALL4 cells were treated with vehicle (DMSO), CHZ868 (300 nM) or ruxolitinib (1000 nM) for 24 hours in duplicate and total RNA was freshly extracted for 3'-RNA-Seq. MHH-CALL4 cells were transduced with constitutive (pLMS-GFP) retroviral vectors harbouring shRNAs targeting JAK2 (shJAK2.209 or shJAK2.2826) or scrambled (shSCR) in duplicate and GFP+ cells were harvested at day 5 post-transduction for 3'-RNA-Seq.
|
| |
|
| Contributor(s) |
Kim S, Johnstone R |
| Citation(s) |
29907650 |
| |
| Submission date |
Aug 11, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
SANGKYU KIM |
| E-mail(s) |
sang-kyu.kim@petermac.org
|
| Organization name |
PETER MACCALLUM CANCER CENTRE
|
| Department |
RESEARCH
|
| Lab |
GENE REGULATION
|
| Street address |
305 GRATTAN ST
|
| City |
MELBOURNE |
| State/province |
VICTORIA |
| ZIP/Postal code |
3000 |
| Country |
Australia |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE102535 |
JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias |
|
| Relations |
| BioProject |
PRJNA397984 |
| SRA |
SRP115270 |
Less...
More...